Impact of P53 smtus to response of temozolomide for multiform glioblastomas

objective This study was designed to assess the clinical outcomes of MGMT low expression glioblastomas with different expression level of mutant P53 to the response of temozolomide chemotherapy.Method Glioblastomas with low MGMT expression were treated with surgical resection,radiotherapy and temozolomide capsule chemotherapy.They were divided into high and low mutant P53 expression groups.Patient age,gender,KPS score and extent of resection were anyalzed between the two groups.Correlation between P53 status and control of tumor growth were analyzed by survival analysis.Results No statistically significant difference in age,gender,KPS score or extent of resection existed between the two groups.Patients with both low mutant P53 expression and low MGMT had much longer progression-free survival time to temozolomide capsule than those with high mutant P53 expression and low MGMT(P＜0.05).Overall survival time did not reach statistical significance between the two groups.Conclusions P53 plays a role in chemotherapy resistance to temozolomide.Glioblastoma patients with both low MGMT and low mutant P53 expression have higher progression-free survival time and may have longer term prognosis. Key words: Glioblastoma; Antineoplastic combined chemotheraphy; Temozolomide